Loading clinical trials...
Loading clinical trials...
Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma
Conditions
Interventions
NanoDoce (direct injection)
NanoDoce (intravesical instillation) - Visit 2 Instillation
+2 more
Locations
5
United States
BCG Oncology, PC
Phoenix, Arizona, United States
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions
Baltimore, Maryland, United States
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
UT Health San Antonio
San Antonio, Texas, United States
Start Date
April 2, 2019
Primary Completion Date
November 2, 2021
Completion Date
November 2, 2021
Last Updated
August 14, 2023
NCT06257264
NCT06857175
NCT04693377
NCT06253871
NCT04895709
NCT06948552
Lead Sponsor
NanOlogy, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions